BioCentury
ARTICLE | Clinical News

Cyramza leads to median OS of 8.5 months in AFP-high HCC population

February 1, 2019 12:46 AM UTC

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III REACH-2 trial to treat hepatocellular carcinoma (HCC) in patients with high α fetoprotein (AFP) levels showing that second-line treatment with Cyramza ramucirumab led to a median overall survival (OS), the primary endpoint, of 8.5 months vs. 7.3 months for placebo (p=0.02). Cyramza also significantly improved median progression-free survival (PFS), a secondary endpoint, vs. placebo (2.8 vs. 1.6 months, p<0.0001).

The company previously reported that Cyramza met the OS and PFS endpoints, but did not disclose detailed data. The new data were published in The Lancet Oncology and presented at American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco (see “Lilly’s Cyramza Meets in Biomarker-Selected HCC Population”)...